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article under the CC BY-NC-ND license (Abstract Background/purpose: The effect of aspirin on bone regeneration remains contro-
versial. This study aimed to determine the effect of various concentrations of aspirin on cell
viability, osteogenic differentiation, cell cycle, and apoptosis on ST2 cells to find an effective
range of aspirin for bone regeneration induction.
Materials and methods: Cell viability was measured with MTT assay after being stimulated with
aspirin for 1 day, 2 days, 3 days, 5 days, and 7 days. Alkaline phosphatase (ALP) activity was
measured after cells were treated for 1 day, 3 days, and 7 days. Expression of runt-related
transcription factor 2 (Runx-2) was evaluated using Western-blot analysis at 3 days and 7 days.
Flow cytometry was used for cell cycle and apoptosis measurement after cells were treated for
48 hours.
Results: Lower concentrations of aspirin (1mM and 10mM) promoted cell growth and increased
ALP levels and Runx-2 expression, while higher concentrations (100mM and 1000mM) inhibited
cell growth (P < 0.05), and lost their effect on ALP activity after 3 days, while even showing
an inhibitory effect on the expression of Runx-2. Aspirin at a concentration of 100mM promoted
cell mitosis from the S phase to the G2/M phase, and 1000mM arrested the cell cycle in the
resting phase G0/G1 (P < 0.05). Parallel apoptosis/necrosis studies showed the percentage
of cells in apoptosis decreased dramatically at any dose of aspirin.
Conclusion: A lower dosage of aspirin could promote ST2 cell growth, osteogenic differentia-
tion, and inhibit their apoptosis which indicates that aspirin can be used as an alternative
for bone regeneration.
Copyright ª 2016, Association for Dental Sciences of the Republic of China. Published by Else-
vier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1 Wenhua Road West, Jinan 250012, China.
u.cn (S. Ge).
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316 M. Du et alIntroductionPeriodontitis is an infectious disease of the periodontal
supportive tissues usually accompanied with bone loss. The
current therapy of periodontitis centers on the reduction of
the bacterial load by mechanical and antimicrobial treat-
ment, as well as the regeneration of lost periodontal tis-
sues.1,2 However, bone regeneration is still one of the more
challenging problems in the field of periodontal therapy. It
is reported that nonsteroidal anti-inflammatory drugs
(NSAIDs) may lighten the severity of tissue destruction and
bone loss resulting from periodontal diseases.2,3 Recently, a
study showed that some antiplatelet regents, such as clo-
pidogrel, can enhance periodontal repair by decreasing
inflammation.4 As a member of the NSAID family, aspirin
(acetyl salicylic acid; ASA) is a common drug used for its
analgesic, antipyretic, and anti-inflammatory effects. In
addition to its inhibitory effect on cyclooxygenases and
antiplatelet aggregator effects, high doses of ASA such as
1mM, 5mM, and 10mM have also been shown to inhibit
smooth muscle proliferation, endothelial proliferation/
angiogenesis, and pro-inflammation.5e7 The effects of
NSAIDs on bone tissue were controversial. Some animal
studies showed that NSAIDs could promote bone repair,
while several other studies indicated that aspirin/NSAIDs
could suppress overall bone remodeling, especially at high
doses.8e13 However, it has been advocated that aspirin
treatment is beneficial for bone health by improving bone
mineral density (BMD) in trabecular and cortical bones,14
and one clinical study reported that aspirin users had
elevated whole body BMD (þ4.2%) and total hip BMD
(þ4.6%) compared with nonusers.15 Researchers found
aspirin could promote bone marrow stromal cells (BMSCs) to
differentiate into osteoblasts.16 Unlike some other NSAIDs,
aspirin has no adverse effects on osteoblast growth with
proper dosesdgrowth was only reduced at higher concen-
trations such as 100mM and 1000mM by cell cycle arrest and
apoptosis induction.17
BMSCs are characterized by their self-renewal and mul-
tipotent differentiation capacities, and the published data
indicate that they are widely used in biomedical/bioengi-
neering fields.18 During adult life, BMSCs are a source of
osteoprogenitors. Thus, BMSCs are candidate cells for
evaluating the effects of ASA on bone formation and bone
remodeling. Actually, the effect of aspirin on BMSC growth
remains unclear. ST2 cells are interstitial cells that are
isolated from BC8 mice bone marrow stroma and have the
potency to differentiate into osteoblast-like cells under
appropriate conditions.19 Therefore, the objective of this
study was to analyze the effects of different doses of
aspirin on cell viability, osteogenic differentiation, cell
cycle, and apoptosis of ST2 cells.
Materials and methods
Cell culture
ST2 cells were purchased from Riken Cell Bank (Riken Bio-
Resource Center, Tsukuba, Ibaraki, Japan). Cultures were
kept at 37C in a humidified atmosphere of 95% air and 5%
CO2 and the medium was changed [containing Dulbecco’smodified Eagle’s medium (Hyclone, Logan, UT, USA), 10%
fetal bovine serum (Hyclone), and 1% penicillin/strepto-
mycin (Sigma-Aldrich, Saint Louis, MO, USA)] every 2 days.
When the adherent cells added up to 80%, cells were
treated with a solution of 0.05% trypsin (Sigma-Aldrich) and
0.02% EDTA (Sigma-Aldrich) to subculture by 1:3.
Assessment of cell viability
Cell viability was determined using the MTT method. ST2
cells were seeded at 4  103cells/well into a 96-well plate
(Corning, Corelle City, NY, USA) at a final volume of 100-mL
Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum and 1% penicillin/streptomycin and cultured
at 37C for 24 hours. Subsequently, cells were treated with
various concentrations of aspirin (0mM, 1mM, 10mM,
100mM, and 1000mM; Sigma-Aldrich) for 1 day, 2 days,
3 days, 5 days, and 7 days, respectively. At the end of
treatment, 5-mg/mL MTT (Sigma-Aldrich) was added into
the medium and incubated for 4 hours. After that, the
medium was aspirated and a dark-purple water-insoluble
deposit of formazan crystals appeared. Then, 150-mL
dimethylsulfoxide (Genview, Beijing, China) was added to
dissolve the formazan crystals. Absorbance was measured
at 490 nm with a spectrophotometer (Thermo Fisher Sci-
entific, Waltham, MA, USA).
Osteogenic differentiation assay
Alkaline phosphatase (ALP) activity and runt-related tran-
scription factor 2 (Runx-2) were measured for osteogenic
differentiation. ST2 cells were plated at 4  104cells/well
into six-well plates and treated with aspirin at a dose of
0mM, 1mM, 10mM, 100mM, and 1000mM for 1 day, 3 days, and
7 days. After the treatment, the adhered cells were lysed
by 0.1% triton-X 100 (US Biological, Swampscott, MA, USA)
for 35 minutes. AKP Kit (Nanjing Jiancheng, China) and BCA
Protein Kit (Solarbio, Beijing, China) were used to measure
ALP activity and concentrations of bovine serum albumin
according to the manufacturer’s instructions. Bovine serum
albumin is usually used for establishing a standard curve of
protein concentration.
For the other osteogenesis marker, Runx2, ST2 cells
were cultured in an osteogenesis medium [108M dexa-
methasone (Sigma-Aldrich), 10mM b-glycerophosphate
(Sigma-Aldrich), and 50-ng/mL ascorbic acid (Sigma-
Aldrich)] with different doses of aspirin for 3 days and
7 days, then proteins were extracted from the cells with
ice-cold radioimmunoprecipitation assay lysis buffer
(Solarbio) containing 0.1% phenylmethylsulfonyl fluoride
(Solarbio), followed by centrifugation at 12,000g at 4C for
10 minutes. Samples were subjected to 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred
to polyvinylidene difluoride membranes (GE Amersham,
Fairfield, CT, USA) by electroblotting. Filters were then
blocked in 5% nonfat milk-Tris buffered saline and 0.05%
Tween 20 for 1 hour and incubated with the following pri-
mary antibody overnight: rabbit monoclonal anti-Runx2
antibody (1:500 dilution; ab23981, Abcam, Cambridge,
UK). The bands corresponding to Runx-2 were detected
using a chemiluminescence reagent (Millipore, Darmstadt,
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(1:10,000) was used as a loading control. Images were
collected with Tanon-5200 (Tanon, Shanghai, China).
Cell cycle analysis
Cultured ST2 cells were plated at 3  105 cells/well into a
six-well plate and treated with 0mM, 1mM, 10mM, 100mM,
and 1000mM of aspirin for 48 hours. Cells were detached
from the culture plate by treatment with a solution of
0.05% trypsin and 0.02% EDTA and transferred into a 15-mL
centrifugal tube (Corning). After centrifugation for 10 mi-
nutes at 180g, the cells were washed with cold phosphate
buffered saline (PBS) once. Subsequently, cells were fixed
by ice-cold 70% ethanol for 24 hours at 4C and harvested by
centrifugation and then resuspended in 2-mL cold PBS.
Cells were then incubated at 37C for 30 minutes with
ribonuclease and propidium iodide (PI) according to the
instructions. Finally, samples were analyzed using flow
cytometry (Beckman Coulter Inc., Pasadena, CA, USA).
Apoptosis analysis
Cultured ST2 cells were plated at 2  105 cells/well into a
six-well plate and treated with 0mM, 1mM, 10mM, 100mM,
and 1000mM of aspirin for 48 hours. Cells were then de-
tached from the culture plate and washed with 2-mL cold
PBS. Fluorescein Annexin V (annexin V-FITC) Apoptosis
Detection Kit (BIOBOX, Nanjing, China) was used according
to the manufacturer’s instructions for identifying the
apoptosis marker. Briefly, cells were resuspended in 500 mL
of binding buffer and stained with 5 mL of annexin V-FITC
and 5-mL PI. After incubation at room temperature in the
dark for 10 minutes, cells were analyzed with flow cytom-
etry within 1 hour of staining, with single annexin V-FITC or
PI staining as positive controls and no staining as a negative
control.
Statistical analysis
SPSS (version 17.0; SPSS Inc., Chicago, IL, USA) was used for
data analysis. A one-way analysis of variance and Stu-
dentseNewmaneKeuls test were used for examining the
effects on cell viability, ALP activity, cell cycle, and
apoptosis. The data were given as the mean  standard
deviation for each experiment. For each test, P < 0.05 was
considered statistically significant.Figure 1 Cell morphology observation after recovery. (A) Twent
shapes and large intercellular space was observed; (B) 48h after re
each other into a net, the oval nucleus was in the middle.Results
Cell morphology observation after recovery
From 4 hours to 6 hours after recovery, ST2 cells were
attached to the wall and sprawled out, with a spherical or
rounded triangular shape. After 24 hours, the number of
synapses increased. ST2 cells loosely arranged with long
spindle shapes, and a large intercellular space was
observed (Figure 1A). Forty-eight hours after recovery, cells
proliferated into a large number and connected with each
other into a net. The oval nucleus was observed in the
middle of cell body (Figure 1B and 1C).
Effects of aspirin on cells viability
In the present study, ST2 cells were treated with various
concentrations of aspirin (0mM, 1mM, 10mM, 100mM, and
1000mM) for 1 day, 2 days, 3 days, 5 days, and 7 days. MTT
results demonstrated that proliferation of ST2 cells was
affected by aspirin in a dose- and time-dependent manner.
Compared with the control group, cell viability was signif-
icantly enhanced in aspirin-treated (1mM, 10mM, 100mM, and
1000mM) groups after 1 day and 2 days (P < 0.001 and
P < 0.05, respectively). Significant favorable effect of
lower doses (1mM and 10mM) on cell growth lasted in the
following 3 days, 5 days, and 7 days (P < 0.05). By contrast,
higher concentrations (100mM) had no impact on cell growth
(P > 0.05) from the 3rd day and cell viability was apparently
inhibited by 1000mM of aspirin at the same time point
(P < 0.05; Figure 2).
Effects of aspirin on osteogenic differentiation
ALP activity of ST2 cells increased at all assayed doses after
treatment for 1 day. All doses of aspirin (1mM, 10mM, 100mM,
and 1000mM) promoted ALP activity (7.870  0.558 U/gprot,
9.149  1.423 U/gprot, 9.299  1.425 U/gprot, and
8.978  1.237 U/gprot) compared with the control group
(5.413  0.460 U/gprot; P < 0.05). When cultured for
3 days, ALP levels kept on increasing for the groups treated
with 1mM and 10mM aspirin while higher concentrations
(100mM and 1000mM) of aspirin showed no significant effect
on ALP levels at this time point (Figure 3). Not surprisingly,
lower concentrations (1mM and 10mM) of aspirin significantly
increased ALP activity compared with the higher ones andy-four hours after recovery (100), cells were in long spindle
covery (200); (C) 48h after recovery (100) cells connected
Figure 2 Effect of different doses of aspirin on viability of
ST2 cells (n Z 6). ST2 cells were incubated with various con-
centrations of aspirin for 1 day, 2 days, 3 days, 5 days, and
7 days, respectively. The proliferation of ST2 cells was
measured with MTT assay (490 nm wavelength). Data repre-
sents means  standard deviation (n Z 6, six replicates per
time point for each experimental condition). ** P < 0.01
compared with control (0mM aspirin treatment). OD Z optical
density.
Figure 4 (A) Effect of aspirin on runt-related transcription
factor 2 (Runx-2) expression of ST2 cells. ST2 cells were
cultured in an osteogenesis medium with different doses of
aspirin for 3 days and 7 days; (B)western-blot analysis showed
that on Day 3, all doses of aspirin promoted Runx-2 expression.
On Day 7, only 1mM and 10mM of aspirin increased Runx-2 levels
compared with the control, the higher ones (100mM and
1000mM) showed an inhibitory effect on the contrary. Glycer-
aldehyde 3-phosphate dehydrogenase (GADPH) was used as a
loading control.
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blot analysis showed that in Day 3, all doses of aspirin
promoted Runx-2 expression, while on Day 7 only lower
concentrations of aspirin increased Runx-2 levels compared
with the control, especially 10mM aspirin. By contrast, the
higher concentrations (100mM and 1000mM) had an inhibi-
tion effect on the expression of Runx-2 (Figure 4).
Effects of aspirin on cell cycle
The percentage of cells in each cell cycle phase (G0/G1,
G2/M, and S) was determined with flow cytometry (Figures
5 and 6). No significant effect on the ST2 cell cycleFigure 3 Effect of different doses of aspirin on (alkaline
phosphatase) ALP activity of ST2 cells. ST2 cells were
cultured with various concentrations of aspirin for 1 day,
3 days, and 7 days. Data were normalized for total protein
content to account for the effects. The ALP activity incu-
bated with 1mM and 10mM aspirin significantly increased. Data
represents means  standard deviation (n Z 6, 6 replicates
per time-point for each experimental condition). By one-way
analysis of variance and StudentseNewmaneKeuls test, sig-
nificant differences were shown. * P < 0.05 compared with
control. ** P < 0.01 compared with control. *** P < 0.05 versus
100mM and 1000mM.(P > 0.05) was observed at the lower doses (1mM and 10mM).
Aspirin at a concentration of 100mM induced a higher per-
centage in the division phase (G2/M)dthe proportions of
cells in the G2/M phase in the control group and the 100mM
treated group were 8.125  0.075% and 9.33  0.07%,
respectively (P < 0.05). However, 1000mM aspirin arrested
the cell cycle in resting phase (GO/G1) and induced a
decrease in the proliferative phase (S phase). The mean
percentage of cells in the G0/G1 phase was 75.0  0.9% in
control cultures versus 78.55  1.35% in the 1000mM treated
group (P < 0.05), and 16.95  0.75% versus 14.6  0.30% for
the S phase (P < 0.01; Figure 5). A typical result for cell
cycle distribution treated with different doses of aspirin
[0mM (A), 1mM (B), 10mM (C), 100mM (D), and 1000mM (E)] is
described in Figure 6.Figure 5 Effect of aspirin on cell cycle distribution of ST2
cells. ST2 cells were cultured in serum-free medium for
24 hours and then treated with the indicated concentrations of
aspirin for 48 hours. Flow cytometric analysis showed that
100mM aspirin significantly increased the proportion of cells in
the G2/M phase and G0/G1 phase for 1000mM aspirin. Data was
shown as means  standard deviation (n Z 4, 4 replicates per
time-point for each experimental condition). By one-way
analysis of variance and StudentseNewmaneKeuls test, sig-
nificant differences were shown. * P < 0.05 compared with the
same phase of cell cycle of control.
Figure 6 (A) Control group; (B) typical result for the effect on cell cycle of 1mM; (C) 10mM; (D) 100mM; and (E) 1000mM of aspirin
with flow cytometry.
Table 1 Effect of aspirin on cell apoptosis rate of ST2
cells (n Z 4). Data for the percentage of viable ST2 cells
and apoptic cells treated with aspirin for 48 hour are shown
numerically.
Mean SD P
Control Early ap. 11.5 0.9 e
Negative 86.05 2.45 e
Aspirin 1mM Early ap. 5.3** 0.1 0.0003
Negative 94.3** 0.2 0.0044
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Annexin V and PI were used to measure the number of the
apoptotic cells after culture for 48 hours. The means,
standard deviations, and P values of viable and apoptotic
cells under different doses of aspirin are described in Table
1. The percentage of cells in apoptosis decreased dramat-
ically after treatment with aspirin for 48 hours (P < 0.05).
Figure 7 typically showed the cell percentage in each
quadrant under different conditions [0mM (A), 1mM (B),
10mM (C), 100mM (D), and 1000mM (E)]. The number of viable
cells (Ann V and PI) was counted in the lower left
quadrant (C3), and the percentages of cells in early
apoptosis (Ann Vþ, PI, lower right quadrant C4), late
apoptosis (Ann Vþ , PIþ, upper right quadrant C2), and ne-
crosis (Ann V, PIþ, upper left quadrant C1) were also
determined. These results indicated that all concentrations
of aspirin inhibited cell apoptosis in a short amount of time.Aspirin 10mM Early ap. 5.5** 0.1 0.0003
Negative 93.3** 0.3 0.0070
Aspirin 100mM Early ap. 4.9** 0.9 0.0009
Negative 93.8** 0.9 0.0068
Aspirin 1000mM Early ap. 7.95** 0.25 0.0028
Negative 90.55* 0.55 0.0361
* P < 0.05 compared with control (0mM aspirin treatment).
** P < 0.01 compared with control (0mM aspirin treatment).
ap. Z apoptosis; SD Z standard deviation.Discussion
Periodontitis is a common chronic inflammatory disease
initiated by bacteria which is characterized by the
destruction of connective tissue and alveolar bone. Many
studies have shown that some NSAIDs are commonly used in
bone tissue repair, especially for bone healing and the
treatment of bone fractures.9e12 However, a recentlypublished systematic review demonstrated an adverse ef-
fect of NSAIDs on osteoblasts proliferation.12 It was previ-
ously reported that the dose of NSAIDs is a key factor in the
effect on cell proliferation as well as on cell differentiation
and migration.13
Figure 7 (A) Control group; (B) typical result for the effect on cell apoptosis rate of 1mM; (C) 10mM; (D) 100mM; and (E) 1000mM of
aspirin with flow cytometry. The number of viable cells was counted in the lower left quadrant (C3), early apoptosis in lower right
quadrant (C4), late apoptosis in upper right quadrant (C2), and necrosis in upper left quadrant (C1).
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pacity of ST2 cells from murine bone marrow was signifi-
cantly promoted by 1mM and 10mM of aspirin. However,
higher concentrations of aspirin (1000mM) inhibited cell
proliferation when treated for > 3 days. This result was in
agreement with observations on the effects of aspirin on
endothelial cell proliferation in vitro.7 Moreover, low con-
centrations of aspirin (0.1e1000mM) promoted migration
and adhesion of late endothelial progenitor cells (EPC)
while the high concentrations of aspirin (10,000mM)
decreased EPC proliferation and the migratory capacity of
EPC after treatment for 24 hours.20
According to the acting mechanism, a previous study
indicated that 1mM, 5mM, and 10mM of aspirin inhibited
MSC proliferation and the downregulation of the Wnt/beta-
catenin signal pathway may be involved in growth inhibi-
tion.21 Therefore, lower doses of aspirin have a favorable
effect on cell viability, while higher doses may have an
adverse effect on cell proliferation increasing with time.
Since ALP and Runx-2 are well recognized as biochemical
markers for osteogenesis activity, we examined the change
of ALP and Runx-2 levels of ST2 cells in response to aspirin.
ALP activity increased in a short amount of time treated
with all concentrations of aspirin, but higher concentra-
tions (100mM and 1000mM) lost their effect when cultured
for 3 days. It was the same with the expression of Runx-
2dthe inhibition effect of higher doses of aspirin appearedat Day 7. These results demonstrated that lower doses of
aspirin stimulated ST2 cell differentiation into osteoblast-
like cells but not at higher doses.
The effect of aspirin on the growth of ST2 cells is closely
related to the effects on the cell cycle. Cell numbers in the
proliferative phase (G2/M phase) significantly increased
when treated with 100mM aspirin, which indicated that
100mM aspirin could promote cell proliferation by pro-
ceeding cell mitosis from the S phase to the G2/M phase. By
contrast, the results showed that cell numbers in the
resting phase (G0/G1 phase) were higher than that in the
control group and decreased dramatically in the S phase
after treatment with 1000mM aspirin for 48 hours; thus, the
negative effect of 1000mM aspirin on cell viability can be
explained by cell cycle arrestment in the phase G0/G1.
Annexin V and PI staining showed aspirin could inhibit cell
apoptosis at all concentrations when treated for 48 hours
which is consistent with the result of the MTT assays.
However, apoptosis is almost present in proliferating cells
and molecules acting on cells in the late G1 phase are
required for apoptosis,22 which may be the basis for the
inhibitory effect of 1000mM aspirin in the longer times.
In addition, inflammation in the bone microenvironment
is known to contribute to bone loss. Therefore, decreasing
inflammation in bone marrow might be helpful for inhibiting
bone loss. Aspirin remains the most commonly used medi-
cation for the treatment of inflammation. A well-known
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of prostaglandins (PGs), which play a central role in the
inflammatory response, produced through the cyclo-
oxygenase (COX) pathway. Recent research has suggested
that aspirin directly modifies the action of cyclo-oxygenase
2, changing its activity towards the lipoxygenase pathway,
resulting in the formation of aspirin-triggered lipoxins.
Lipoxins have emerged as mediators of endogenous anti-
inflammatory events and are known to inhibit neutrophil
chemotaxis, superoxide generation, and secretion of
proinflammatory cytokines and proteolytic molecules
including PGs.23 By contrast, some researchers thought PGs
(PGE2 in particular) stimulated bone formation in vivo, and
the suppressive effects of NSAIDs on bone repair are due to
the inhibitory effect of PGs in bone cells.24 Thus, inhibition
of PGs as an anti-inflammatory pathway might not
contribute to bone healing and deserves further research.
Interestingly, some studies demonstrated that aspirin
inhibited inflammatory responses in various cell lines,
including endothelial cells, fibroblasts, and bone marrow
mesenchymal stem cells (BMMSCs) through the inhibition of
reactive oxygen species generation or NF-kappaB
activation.25e27
Moreover, aspirin could promote the immunomodulatory
function of BMMSCs by upregulation of regulatory T cells
and downregulation of Th17 cells via 15-deoxy-delta-12,14-
prostaglandin J2/peroxisome proliferator-activated recep-
tor-g/transforming growth factor-b1 pathway.28 By
contrast, a study which demonstrated that the pharmaco-
logic regulation of BMMSCs by aspirin might offer an
approach for estrogen-deficient osteoporosis treatment and
showed activated T lymphocytes induced BMMSCs apoptosis
through the Fas/FasL pathway, but aspirin treatment could
induce activated T-cell death in vitro, and promote
osteogenesis of BMMSCs by upregulating telomerase activ-
ity. This research also suggested long-term aspirin treat-
ment could improve BMD in ovariectomy mice, and inhibit
osteoclast activities.29
From a clinical standpoint, a cross-sectional investiga-
tion suggest that long-term (> 6 months) low dose (75 mg/
d) aspirin therapy for humans may reduce the risk of peri-
odontal attachment loss.30 The highest plasma drug con-
centration of 75 mg/d is 40mM, which is in the
concentration range for promoting cell proliferation and
differentiation in our study. A randomized trial showed that
low-dose aspirin (81 mg/d) contributed to improving mod-
erate periodontitis and gingival inflammation supple-
mented with docosahexaenoic.31 These indicated a
therapeutic dose range (1e100mM) used in the clinic for
bone cell proliferation as well as differentiation.
In conclusion, this study provided clear evidence that
aspirin at lower doses promotes BMSC growth and en-
hances osteogenic differentiation of ST2 cells. Cell growth
only decreased at higher doses by cell cycle arrest and
showed a trend of apoptosis induction. Together with its
anti-inflammatory effect, ASA could be applied in the
treatment of periodontitis with bone loss. However, we
need further research to examine the effect of aspirin on
BMSC adhesion and migration and to evaluate the accu-
rate doses of aspirin to promote bone regeneration in
in vivo studies.Conflicts of interest
The authors have no conflicts of interest relevant to this
article.Acknowledgments
This study was supported by the National Natural Science
Foundation of China (Numbers 81100756 and 81371157)
and Science and Technology Program of Shandong Prov-
ince (Number 2014GSF118075). The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript. We would like
to acknowledge the support of Dr Faliang Zhu with the
flow cytometry.References
1. Slots J, Ting M. Systemic antibiotics in the treatment of peri-
odontal disease. Periodontol 2000 2002;28:106e76.
2. Elkhouli AM. The efficacy of host response modulation therapy
(omega-3 plus low-dose aspirin) as an adjunctive treatment of
chronic periodontitis (clinical and biochemical study). J Peri-
odontal Res 2011;46:261e8.
3. Shiloah J, Bland PS, Scarbecz M, Patters MR, Stein SH,
Tipton DA. The effect of long-term aspirin intake on the
outcome of nonsurgical periodontal therapy in smokers: a
double-blind, randomized pilot study. J Periodontal Res 2014;
49:102e9.
4. Coimbra LS, Steffens JP, Rossa Jr C, Graves DT,
Spolidorio LC. Clopidogrel enhances periodontal repair in
rats through decreased inflammation. J Clin Periodontol
2014;41:295e302.
5. Khaidakov M, Szwedo J, Mitra S, et al. Antiangiogenic and
antimitotic effects of aspirin in hypoxia-reoxygenation modu-
lation of the LOX-1-NADPH oxidase axis as a potential mecha-
nism. J Cardiovasc Pharmacol 2010;56:635e41.
6. Marra DE, Simoncini T, Liao JK. Inhibition of vascular smooth
muscle cell proliferation by sodium salicylate mediated by
upregulation of p21 (Waf1) and p27 (Kip1). Circulation 2000;
102:2124e30.
7. Pearce HR, Kalia N, Bardhan KD, Brown NJ. Effects of aspirin
and indomethacin on endothelial cell proliferation in vitro. J
Gastroenterol Hepatol 2003;18:1180e7.
8. Lack WD, Fredericks D, Petersen E, et al. Effect of aspirin on
bone healing in a rabbit ulnar osteotomy model. J Bone Joint
Surg Am 2013;95:488e96.
9. Krayer JW, Leite RS. Nonsurgical chemotherapeutic treatment
strategies for the management of periodontal disease. Dent
Clin North Am 2010;54:13e33.
10. Aspalli SS, Shetty VS, Parab PG, Nagappa G, Devnoorkar A,
Devarathnamma MV. Osteoporosis and periodontitis: is there a
possible link? Indian J Dent Res 2014;25:316e20.
11. Wei JS, Zeng R, Chen SY, Lin H, Wu SK, Zheng JC. Effects of
aspirin on fracture healing in OPF rats. Asian Pac J Trop Med
2014;7:801e5.
12. Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonste-
roidal anti-inflammatory drugs affect bone healing? A critical
analysis. Sci World J 2012;2012:606404.
13. Muller M, Raabe O, Addicks K, Wenisch S, Arnhold S. Effects of
nonsteroidal anti-inflammatory drugs on proliferation, differ-
entiation and migration in equine mesenchymal stem cells.
Cell Biol Int 2011;35:235e48.
322 M. Du et al14. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in
older women: effect on bone mineral density and fracture risk.
Study of osteoporotic fractures research group. J Bone Miner
Res 1996;11:29e35.
15. Carbone LD, Tylavsky FA, Cauley JA, et al. Association between
bone mineral density and the use of nonsteroidal anti-
inflammatory drugs and aspirin: impact of cyclooxygenase
selectivity. J Bone Miner Res 2003;18:1795e802.
16. Papathanasopoulos A, Kouroupis D, Henshaw K,
McGonagle D, Jones EA, Giannoudis PV. Effects of antith-
rombotic drugs fondaparinux and tinzaparin on in vitro
proliferation and osteogenic and chondrogenic differentia-
tion of bone-derived mesenchymal stem cells. J Orthop Res
2011;29:1327e35.
17. De Luna-Bertos E, Ramos-Torrecillas J, Garcı´a-Martı´nez O,
Dı´az-Rodrı´guez L, Ruiz C. Effect of aspirin on cell growth of
human MG-63 osteosarcoma line. Sci World J 2012;2012:
834246.
18. Bradamante S, Barenghi L, Maier JA. Stem cells toward the
future: the space challenge. Life (Basel) 2014;4:267e80.
19. Itoh F, Aoyagi S, Furihata-Komatsu H, et al. Clodronate stim-
ulates osteoblast differentiation in ST2 and MC3T3-E1 cells and
rat organ cultures. Eur J Pharmacol 2003;477:9e16.
20. Liu ZZ, Li GQ, Liu M, Sun SX, An GY, Dong NZ. Effect of aspirin
on function of human umbilical cord blood-derived late endo-
thelial progenitor cell. Zhongguo Shi Yan Xue Ye Xue Za Zhi
2013;21:1032e7.
21. Wang Y, Chen X, Zhu W, Zhang H, Hu S, Cong X. Growth inhi-
bition of mesenchymal stem cells by aspirin: involvement of
the WNT/beta-catenin signal pathway. Clin Exp Pharmacol
Physiol 2006;33:696e701.
22. Alenzi FQ. Links between apoptosis, proliferation and the cell
cycle. Br J Biomed Sci 2004;61:99e102.23. Yao C, Yang D, Wan Z, et al. Aspirin-triggered lipoxin A4 at-
tenuates lipopolysaccharide induced inflammatory response in
primary astrocytes. Int Immunopharmacol 2014;18:85e9.
24. Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ. Effects of
nonsteroidal anti-inflammatory drugs and prostaglandins on
osteoblastic functions. Biochem Pharmacol 1999;58:983e90.
25. Wang X, Lu J, Khaidakov M, et al. Aspirin suppresses cardiac
fibroblast proliferation and collagen formation through down-
regulation of angiotensin type 1 receptor transcription. Tox-
icol Appl Pharmacol 2012;259:346e54.
26. Wu Y, Zhai H, Wang Y, et al. Aspirin-triggered lipoxin A4 at-
tenuates lipopolysaccharide-induced intracellular ROS in BV2
microglia cells by inhibiting the function of NADPH oxidase.
Neurochem Res 2012;37:1690e6.
27. Zhang F, Lu M, Wang H, Ren T. Aspirin attenuates angiotensin
II-induced inflammation in bone marrow mesenchymal stem
cells via the inhibition of ERK1/2 and NF-kB activation. Biomed
Rep 2013;1:930e4.
28. Tang J, Xiong J, Wu T, et al. Aspirin treatment improved
mesenchymal stem cell immunomodulatory properties via the
15d-PGJ2/PPARg/TGF-b1 pathway. Stem Cells Dev 2014;23:
2093e103.
29. Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based
intervention as a new approach to osteoporosis treatment in
rodents. PLoS One 2008;3:e2615.
30. Faizuddin M, Tarannum F, Korla N, Swamy S. Association be-
tween long-term aspirin use and periodontal attachment level
in humans: a cross-sectional investigation. Aust Dent J 2012;
57:45e50.
31. Naqvi AZ, Hasturk H, Mu L, et al. Docosahexaenoic acid and
periodontitis in adults: a randomized controlled trial. J Dent
Res 2014;93:767e73.
